Insider transactions

Joseph Klein III

CIK 1206369 · last filed 2026-07-06

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$2.91M
Companies
8
Total Filings
145
Lifetime Open-Market Net
-$18.50M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

IONS price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE COURT
CARLSBAD, CA 92010
Related Filers
IONIS PHARMACEUTICALS INC — 84 joint filings, latest 2026-07-06
PDL BIOPHARMA, INC. — 27 joint filings, latest 2009-11-06
BIOMARIN PHARMACEUTICAL INC — 16 joint filings, latest 2010-03-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IONS Director 22,633 $40.15 $908.7K -$12.33M 43 2026-07-06
AKCEA THERAPEUTICS, INC. (AKCA) Delisted Director — — — $0 3 2020-10-13
IONIS PHARMACEUTICALS INC (ISIS) Delisted Director 5,643 — — -$3.38M 21 2015-11-12
SAVIENT PHARMACEUTICALS INC (SVNT) Delisted Director 17,388 — — -$573.6K 14 2010-07-21
OSI PHARMACEUTICALS INC (OSIP) Delisted Director 0 — — -$698.3K 13 2010-06-09
BMRN Director 35,000 $57.13 $2.00M -$1.33M 12 2010-03-10
PDL BIOPHARMA, INC. (PDLI) Delisted Director 19,484 — — -$36.2K 26 2009-11-06
NPS PHARMACEUTICALS INC (NPSP) Delisted Director 15,000 — — -$154.7K 4 2007-05-25

Recent Filings · Page 5 of 15

145 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-07-03 IONS Mixed +2,889 $0 EDGAR
2018-07-03 IONS Mixed +2,667 $0 EDGAR
2018-03-30 IONS Mixed — -$43.5K EDGAR
2018-03-16 IONS Mixed −900 -$75.4K EDGAR
2018-03-01 IONS Mixed — -$49.1K EDGAR
2018-02-16 IONS Mixed — -$40.4K EDGAR
2018-01-31 IONS Mixed — -$52.0K EDGAR
2018-01-17 IONS Mixed — -$51.0K EDGAR
2018-01-02 IONS Mixed — -$66.3K EDGAR
2017-12-19 IONS Mixed — -$69.7K EDGAR
Showing 41–50 of 145
Page 5 of 15
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.